InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Gene Therapy Platform Market– (By Platform Type (Viral Vector Platforms, Non-Viral Vector Platforms), By Therapeutic Application, By Delivery Mode, By End Use, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2034.”
According to the latest research by InsightAce Analytic, the Global Gene Therapy Platform Market is valued at USD 2.2 Bn in 2024 , and it is expected to reach USD 9.8 Bn by 2034 , with a CAGR of 16.5% during the forecast period of 2025-2034.
Check this Report Brochure : https://www.insightaceanalytic.com/request-sample/3082
One of the most revolutionary developments in contemporary medicine has been the quick rise of gene therapy. Gene therapy offers long-term therapeutic options by altering, substituting, or silencing defective genes that cause disease development, especially for rare or previously incurable genetic disorders. The underlying technologies and delivery methods that make these medicines possible, such as gene editing systems viral and non-viral vectors, are included in the gene therapy platform market.
Rapid technical improvements, the rise in chronic and hereditary disorders, increased funding and investments in biopharmaceutical research, and regulatory frameworks that promote quicker approvals are some of the main factors driving this growth. Additionally, the growing number of FDA approvals for gene therapies targeting rare and genetic disorders has confirmed the clinical potential of these platforms, promoting R&D and investment. Scalable gene therapy platforms that facilitate the effective creation and production of customized therapies are attracting increasing investment from businesses.
List of Prominent Players in the Gene Therapy Platform Market:
- Lonza
- BioIT
- L7 Informatics, Inc.
- TrakCel
- IDBS
- Sarepta Therapeutics, Inc.
- CRISPR Therapeutics
- Precision BioSciences
- AstraZeneca
- Andelyn Biosciences
- Novartis
- SAP SE
- Autolomous Ltd
- DEEP GENOMICS
- ElevateBio
- Renova Therapeutics
- Hypertrust Patient Data Care (Part of Accenture)
- IBM
- Others
Market Dynamics:
Drivers-
The market for gene therapy platform is expanding as a result of the sharp rise in cancer and other target disease incidences, which necessitates efficient therapies. The increase in cancer incidence worldwide is likely to drive the expansion of the gene therapy platform market throughout the forecast period. The American Cancer Society, for example, estimates that in January 2022, there will be 609,360 cancer-related deaths in the United States, or about 1,670 deaths per day, and 1.9 million new cancer diagnoses.
Lung, bowel, prostate, and female breast cancer are the four most prevalent cancer forms globally, making up about 43% of all new cancer cases. Lung, prostate, bowel, and female breast cancer are the four most prevalent cancer forms globally, making up about 43% of all new cancer cases. As a result, it is projected that the global increase in the prevalence of cancer will increase demand for gene therapy platforms in the years to come. One of the best cancer treatments available is gene therapy. To either kill the malignant cell or halt its growth, new genes are inserted into the surrounding tissue or directly into the diseased cell itself.
Challenges:
The gene therapy platform has considerable manufacturing and scalability issues despite its potential. It takes highly specialized bioprocessing infrastructure, strict quality control, and skilled workers to produce viral vectors, particularly AAV and lentivirus. This leads to significant operational and capital costs, which frequently restrict access for smaller biotech companies. Additionally, the customised nature of autologous treatments necessitates customised production, which increases the expense and time commitment. The situation is further complicated by inconsistent yields, purifying bottlenecks, and obstacles related to regulatory compliance. All of these elements work together to slow down the commercial rollout and create affordability issues, particularly in areas with lower incomes.
Regional Trends:
The North American gene therapy platform market is expected to hold a significant market share in terms of revenue. The primary drivers of the market’s expansion are the increasing number of government and private investments, advancements in gene therapy research and development, and the rising prevalence of target diseases. Additionally, a significant portion of the global gene therapy platform market is attributed to North America’s presence of important industry participants. Additionally, over the projection period, Europe is expected to increase at the fastest rate, driven by advanced research and the region’s growing focus on genetically based medications and personalised therapy. European governments and institutions are investing in biotech, particularly in the UK, Germany, and France, as gene therapy delivery systems are included in research programs targeted at diseases including cancer, cardiovascular problems, and uncommon genetic conditions.
Recent Development:
- February 2025: Andelyn Biosciences expands its AAV Curator platform to further innovate gene therapy. Under the terms of the agreement, Andelyn is authorized to conduct research and development services using Stanton Lab CNS capsids for its clients who are creating gene treatments.
- December 2024: MRC created its first two Centres of Research Excellence with the goal of developing cutting-edge treatments for diseases that are now incurable. The MRC CoREs bring together leading academic and industry expertise to speed up clinical application and translational research of advanced therapeutics. This promotes innovation, infrastructure development, and regulatory advancements that directly benefit and grow the gene therapy platform industry.
- May 2023: The US-based software business Form Bio, which specializes in life sciences, introduced FORMsightAI, a new suite of AI-based solutions for forecasting and maximizing the production results of cell and gene therapy structures. The full-service solution combines state-of-the-art, flexible AI models with Form Bio’s foundational platform and a proficient group of computational life sciences professionals with expertise in data science, bioinformatics, and biology. Common problems that cell and gene therapy companies encounter include build truncations and manufacturing contaminations, which are significant contributors to unacceptable low manufacturing yields, protracted time to market, and issues with therapeutic safety. FORMsightAI solves these issues.
Segmentation of Gene Therapy Platform Market-
Gene Therapy Platform Market- By Platform
- Viral Vector Platforms
- Adenovirus
- Adeno-associated Virus (AAV)
- Retrovirus
- Lentivirus
- Herpes Simplex Virus (HSV)
- Non-Viral Vector Platforms
- Electroporation & Microinjection Platforms
- Polymer-based Delivery Systems
- Lipid Nanoparticles (LNPs)
- Naked DNA/RNA Delivery
- Gene Editing Platforms
- TALENs
- CRISPR-Cas Systems
- ZFNs
Gene Therapy Platform Market- By Delivery Mode
- In Vivo Gene Therapy
- Ex Vivo Gene Therapy
- Allogeneic Cell-Based Gene Therapy
- Autologous Cell-Based Gene Therapy
- In-situ Gene therapy
Gene Therapy Platform Market- By Application
- Cardiovascular Diseases
- Oncology
- Rare Genetic Disorders
- Neurological Disorders
- Ophthalmic Diseases
- Hematological Disorders
- Musculoskeletal Disorders
- Infectious Diseases
Gene Therapy Platform Market- By End-User
- Hospitals & Gene Therapy Centers
- Academic & Research Institutions
- Pharmaceutical & Biotechnology Companies
- Contract Development & Manufacturing Organizations (CDMOs)
Gene Therapy Platform Market- By Region
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
